Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni, +11

New England Journal of Medicine

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer, +17

The Lancet

Lymphoid NeoplasiaRituximab Versus ChopOncologyMantle-cell LymphomasMetronomic Therapy +8

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

Véronique Dièras, David Miles, Sunil Verma, +9

The Lancet Oncology

Breast OncologyOncologyDescriptive AnalysisBreast CancerCancer Treatment +3

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Ian E. Krop, Nancy U. Lin, Kimberly Blackwell, +7

Annals of Oncology

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias Rummel, N. Niederle, Georg Maschmeyer, +16

Blood

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

Mathias Rummel, Ulrich Kaiser, Christina Balser, +16

The Lancet Oncology

Lymphoid NeoplasiaOncologyMantle-cell LymphomasPathologyRelapsed Indolent +6

Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

Manfred Welslau, Véronique Dièras, Joohyuk Sohn, +6

Cancer

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Nora Liebers, Johannes Duell, Donnacha Fitzgerald, +34

Blood Advances

Cell TherapyImmunologyPathologyPola BridgingImmunotherapy +17

Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.

Ralf‐Dieter Hofheinz, Georg Martin Haag, Thomas J. Ettrich, +17

Journal of Clinical Oncology

Surgical OncologyEsophageal CancerCancer ManagementSurgeryPharmacotherapy +14

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.

Mathias Rummel, Georg Maschmeyer, Arnold Ganser, +16

Journal of Clinical Oncology

Hematological MalignancyLymphoid NeoplasiaSurgical OncologyOncologyOverall Survival +12